Last update Aug. 20, 2022
It is a dihydropyridine-type calcium channel blocker. It is used in the treatment of hypertension. Oral administration once daily.
At latest update no published data were found on excretion into breast milk.
Its high plasma protein binding capacity makes it unlikely any passage to the breast milk, however, its high lipid solubility (Rosillon 1998) facilitates excretion into it.
Oral bioavailability is increased when administered with a fatty meal (Rosillon 1998), which would increase the oral absorption in the infant.
Evidence on other antihypertensive drugs of the same family and similar structure, pharmacokinetics and action profile (nifedipine, nimodipine, nicardipine) has shown that they are excreted into milk in non-significant amount.
Until more extensive published data about this drug regarding breastfeeding are available a safer alternative drug should be used, especially during the neonatal period and/or in case of premature infants.
Suggestions made at e-lactancia are done by APILAM team of health professionals, and are based on updated scientific publications. It is not intended to replace the relationship you have with your doctor but to compound it. The pharmaceutical industry contraindicates breastfeeding, mistakenly and without scientific reasons, in most of the drug data sheets.
Your contribution is essential for this service to continue to exist. We need the generosity of people like you who believe in the benefits of breastfeeding.
Thank you for helping to protect and promote breastfeeding.
e-lactancia is a resource recommended by Academy of Breastfeeding Medicine - 2012 of United States of America
Would you like to recommend the use of e-lactancia? Write to us at corporate mail of APILAM